A2A Pharmaceuticals
A2A Pharmaceuticals is a clinical-stage oncology company focused on leveraging proprietary computational systems, including AI, to accelerate the development of novel drug alternatives for life-threatening diseases. Their lead asset, AO-252, is a PPI inhibitor of TACC3, a first-in-class program targeting ovarian, triple-negative, and endometrial cancers. The company has observed significant tumor reduction in Phase 1 trials and is expanding to include prostate, gastric, sarcoma, and brain metastasis patients. A2A Pharmaceuticals also focuses on antibiotics targeting biosynthetic enzymes in gram-negative bacteria. Their proprietary SCULPT™ platform systematically builds and evaluates small molecule libraries to identify drug candidates with optimal properties. The company has achieved significant milestones, including FDA IND clearance for their TACC3 program and the IPO of their spin-off, Biomea Fusion.
A2A Pharmaceuticals
A2A Pharmaceuticals is a clinical-stage oncology company focused on leveraging proprietary computational systems, including AI, to accelerate the development of novel drug alternatives for life-threatening diseases. Their lead asset, AO-252, is a PPI inhibitor of TACC3, a first-in-class program targeting ovarian, triple-negative, and endometrial cancers. The company has observed significant tumor reduction in Phase 1 trials and is expanding to include prostate, gastric, sarcoma, and brain metastasis patients. A2A Pharmaceuticals also focuses on antibiotics targeting biosynthetic enzymes in gram-negative bacteria. Their proprietary SCULPT™ platform systematically builds and evaluates small molecule libraries to identify drug candidates with optimal properties. The company has achieved significant milestones, including FDA IND clearance for their TACC3 program and the IPO of their spin-off, Biomea Fusion.